Abstract | Thyroid carcinoma is the most common endocrine malignancy, and its incidence is continuing to increase. Most thyroid carcinomas contain one of several known driver mutations, such as the Val600Glu substitution in B-Raf, Ras mutations, RET gene fusions, or PAX8-PPARG gene fusions. The PAX8-PPARG gene fusion results in the production of a Pax-8-PPAR-γ fusion protein (PPFP), which is found in approximately onethird of follicular thyroid carcinomas, as well as some follicular-variant papillary thyroid carcinomas. In vitro and in vivo evidence indicates that PPFP is an oncoprotein. Although specific mechanisms of action remain to be defined, PPFP is considered to act as a dominant-negative inhibitor of wild-type PPAR-γ and/or as a unique transcriptional activator of subsets of PPAR-γ-responsive and Pax-8-responsive genes. Detection of the fusion transcript in thyroid nodule biopsy specimens can aid clinical decision-making when cytological findings are indeterminate. The PPAR-γ agonist pioglitazone is highly therapeutic in a transgenic mouse model of PPFPpositive thyroid carcinoma, suggesting that PPAR-γ agonists might be beneficial in patients with PPFP-positive thyroid carcinomas.
Introduction
Thyroid carcinoma is the most common endocrine malig nancy. The American Cancer Society estimates that ~62,980 new cases of thyroid carcinoma (47, 790 in women and 15, 190 in men) and ~1,890 deaths from thy roid carcinoma (1,060 women and 830 men) will occur in the USA in 2014. 1 Moreover, the incidence of thyroid carcinoma has more than doubled since 1990. This trend largely represents increased diagnosis as a result of wide spread use of imaging techniques (such as CT and ultra sonography) that enable the incidental detection of small, nonpalpable thyroid nodules, as well as the increased use of ultrasonographyguided fine needle aspiration (FNA) biopsy and cytological analysis to investi gate these nodules. Still, at least part of the increase comes from finding a greater number of large tumours. 2 Population studies suggest that 3-8% of asympto ma tic adults have thyroid nodules. [3] [4] [5] [6] [7] [8] [9] [10] These nodules can be detected by palpation or, more commonly, by imaging, especially in elderly adults. 3, 4, [7] [8] [9] 11, 12 In addition to carci nomas, thyroid nodules could represent benign hyper plasia or benign follicular adenomas; how ever, whether adenomas have malignant potential is unclear. Approxi mately 95% of thyroid nodules are benign, and an impor tant clinical challenge is to accurately iden tify the ~5% that are malignant. Currently, FNA biopsy of thy roid nodules followed by cytological examination of the aspirate provides an accurate diagnosis as to whether the nodule is malignant or benign in most samples, but ~25% of nodules can not be accurately diagnosed by FNA cytology. [3] [4] [5] [6] [7] [8] [9] [10] As our understanding of the molecu lar pathology of thyroid cancer improves, new molecular diagnostic tests are being developed that have the poten tial to improve the cytological analysis of FNA biopsy samples. In addition, advances in our understanding of the molecular pathology of thyroid cancer are leading to the development of improved prognostic markers and novel targeted therapies.
The vast majority of thyroid cancers contain one of a small number of driver mutations, such as the Val600Glu substitution in BRaf (widely known as BRAF V600E ), Ras mutations, RET gene fusions, or PAX8-PPARG gene fusions. In this Review, we focus on the PAX8-PPARG rearrangement, which is found in ~30-35% of folli cular thyroid carcinomas, as well as in some follicular variant papillary thyroid carcinomas. We summarize the structure and function of the PAX8 and PPARG genes and their protein products-paired box protein Pax8 and peroxi some proliferatoractivated receptor γ (PPARγ)-focusing on their implications for under standing the role of the Pax8-PPARγ fusion protein (PPFP). We discuss the oncogenic mechanisms medi ated by PPFP, the role of fusion transcript detection in the diagnostic evaluation of thyroid nodules, and the potential of PPFP as a therapeutic target. thyroid carcinomas (FTC, ~10% prevalence) and ana plastic (undifferentiated) thyroid carcinomas (ATC, 1-2% prevalence).
PTC and FTC are usually well differentiated, although some are poorly differentiated. Histological subtypes of PTC include classical, follicularvariant, tallcell and others. ATC are the rarest but most aggressive type of thyroid carcinoma, and patients with these tumours have a median survival of only ~6 months. In addition to the above tumours, ~3-5% of thyroid carcinomas originate from the calcitoninproducing parafollicular C cells. These tumours are called medullary thyroid carcinomas.
Gene mutations in thyroid carcinoma
In the future, the classification of follicularcellderived thyroid carcinomas might be based upon underlying genetic changes as well as histological features, since the additional genetic information has the potential to improve the uniformity and objectivity of diagnostic subtypes, as well as to provide information relevant to prognosis and therapy. BRAF V600E is the most common driver mutation in thyroid cancer, [13] [14] [15] and approximately 40-45% of PTC contain this mutation. BRAF V600E is especially common in tallcell PTC and is also found in classic PTC, but it is uncommon in follicularvariant PTC. 16, 17 RET gene fusions are also found in PTC, and are particularly common in radiationinduced cancers. [18] [19] [20] [21] Ras mutations are found primarily in follicularvariant PTC, FTC and benign follicular adenomas. [22] [23] [24] The PAX8-PPARG gene fusion is found in 30-35% of FTC [25] [26] [27] as well as a substantially smaller fraction of follicularvariant PTC. 25, 28, 29 This rearrangement is also occasionally found in follicular adenomas. 26, 27, 30 Thus, Ras mutations and PAX8-PPARG gene fusions are found in the same histological types of thyroid tumours, although Ras mutations are substantially more common than PAX8-PPARG gene fusions in follicular adenomas.
Another chromosomal rearrangement invol ving PPARG, in this case resulting in a gene fusion with CREB3L2, has been found in a very small number of FTC. 31 The existence of two different gene fusions invol ving PPARG in FTC suggests that the PPARγ por tion of the resulting fusion proteins is important to the m echanism of carcinogenesis.
Additional mutations accumulate as thyroid carcino mas become less differentiated. Anaplastic carcinomas probably arise from preexisting, welldifferentiated carci nomas through the acquisition of further abnor malities, such as mutations in TP53 (which encodes p53) [32] [33] [34] [35] or abnormalities in βcatenin signal ling. [36] [37] [38] Activation of the phosphatidylinositide 3kinase (PI3K)-Akt pathway is also common and can occur through a num ber of mechanisms, such as activating mutations in PIK3CA (which encodes the catalytic αsubunit of PI3K) or AKT1, or loss of PTEN expression through gen etic or epigenetic mechanisms. [39] [40] [41] [42] [43] PI3K-Akt pathway ac tivation is also frequent in FTC. 42, 44, 45 Function and structure of Pax-8
Pax8 belongs to the paired box family of transcrip tion factors. This protein is necessary for normal thy roid development, and in the mature thyrocyte Pax8 drives the expression of many thyroidspecific genes, such as TG (which encodes thyroglobulin), TPO (which encodes thyroid peroxidase) and SLC5A5 (which encodes the sodium iodide symporter). 46 Although Pax8 is expres sed in the developing brain and kidney, the only abnor mality in Pax8 -/-mice is the absence of a thyroid gland. PAX8 mutations are also a cause of congenital hy pothyroidism in humans. 47 The PAX8 gene has 12 exons, and the translational start codon is in exon 2 ( Figure 1 ). The DNAbinding domain of Pax8, which comprises the paired domain, is found at the amino terminus of the protein, encoded by exons 3, 4 and the beginning of exon 5. Alternative splicing of exons 8-10 can potentially result in the pro duction of five different RNA transcript and protein isoforms, denoted Pax8A-Pax8E. Pax8B lacks exon 9, but its sequence (NM_013951) has been suppressed from the NIH genesequence database GenBank owing to insufficient evidence of its existence. Nonetheless, one of the known splice variants of PPFP described below Figure 1 | The PAX8 gene and its protein isoforms. The PAX8 gene consists of 12 exons (not drawn to scale). All 12 exons are transcribed, but alternative splicing of PAX8 RNA results in five distinct mRNAs and protein isoforms (Pax-8A-Pax-8E). Exons 3, 4 and the 5' end of exon 5 encode a DNA-binding domain, whereas exons 10 and 11 encode a transcriptional activation domain. In Pax-8B, exon 9 is absent, but this deletion does not alter the downstream reading frame. Pax-8C utilizes an alternative 5' splice site within exon 9, which results in a reading frame shift (dark green) and an early stop codon in exon 11. In Pax-8D and Pax-8E, exons 8-9 and 8-10 are deleted, respectively, which results in truncated proteins and a reading frame shift identical to that of Pax-8C. Abbreviation: aa, amino acid number.
is of the Pax8B type (that is, lacking exon 9). Of note, deletion of exon 9 does not alter the reading frame of downstream exons. Pax8A is the longest isoform and includes exons 2-12. Pax8C utilizes an internal splice site in the 5' region of exon 9, which results in a shortened exon 9, and a reading frame shift that also alters (and shortens) the carboxyl terminal end of the protein, such that the stop codon occurs in exon 11. Pax8D lacks exons 8 and 9, and Pax8E lacks exons 8, 9 and 10. Pax8D and Pax8E are shorter than Pax8C, but have a reading frame shift iden tical to that of Pax8C. Pax8A and Pax8B contain a tran scriptional activation domain encoded by exons 10-11 that is rich in serine, threonine and tyro sine residues and is not present in the other isoforms. 48 Accordingly, transfection data indicate that Pax8A and Pax8B have greater transcriptional activity than Pax8C. 49 Function and structure of PPAR-γ PPARγ belongs to the nuclear receptor family of tran scription factors. This protein is the master regulator of adipogenesis, as well as a potent modulator of whole body lipid metabolism and insulin sensitivity. 50, 51 Fatty acids and eicosanoids, such as the cyclopentenone prosta glandin 15deoxyΔ 12,14 prostaglandin J 2 , can act as endogenous ligands for PPARγ. [52] [53] [54] [55] [56] PPARγ has addi tional functions, such as antiinflammatory activity. 57 In addition, some evidence (discussed later) indicates that PPARγ might act as a tumour suppressor.
PPARγ has the classic structure of a nuclear hormone receptor: an aminoterminal regulatory AB domain, a centrally located zinc finger DNAbinding domain, and a ligandbinding and transcriptionregulatory domain that occupies the carboxylterminal half of the protein ( Figure 2 ). The PPARG gene has two promoters, which results in the production of two different protein iso forms, PPARγ1 and PPARγ2. PPARγ2 is identical to PPARγ1 except that it has a unique 30aminoacid addition at its amino terminus. The proteins seem to have similar functions in transfection experiments, 58 but their expression patterns differ. PPARγ1 is broadly expressed, whereas PPARγ2 is expressed specifically in adipocytes. 59, 60 The PAX8-PPARG fusion gene and protein
The PAX8-PPARG rearrangement is created by a trans location between chromosomal regions 2q13 and 3p25, which contain PAX8 and PPARG, respectively (Figure 3) . 61 Typically, the translocation fuses PAX8 intron 10 to the intron immediately preceding exon 1 of PPARγ1. The PAX8 promoter, which is highly active in thyroid follicular cells, drives the expression of the fusion transcript, resulting in high levels of expression of both the PAX8-PPARG mRNA and PPFP. 62 PPFP consists of an aminoterminal Pax8 frag ment encoded by exons 2-10 that is fused in frame to fulllength PPARγ1. The Pax8 portion is essentially a truncated version of Pax8A that lacks much of its c arboxyl terminal activation domain. However, alter native splicing of the Pax8 part of the fusion transcript can result in multiple PPFP isoforms within the same tumour. Speci fically, PPFP transcripts including Pax8 exons 1-8, 1-9, and 1-8 plus 10 (minus exon 9) have been detected and all maintain the PPARγ1 reading frame. 61 Some studies have reported expression of one of these shorter isoforms without expression of isoforms contain ing exon 10. 27, 63 In these cases, whether the actual chro mosomal translocation site was still in PAX8 intron 10, or in introns 8 or 9 is not known. These findings are important to consider when designing PCR primers for the de tection of various PAX8-PPARG transcripts.
Detection of PPFP in thyroid tumours
Since PPARγ is expressed at very low levels in the nor mal thyroid, overexpression of PPARγ detected by immuno histochemistry provides evidence for the pres ence of PPFP. However, this method is not entirely speci fic, and definitive testing for PPFP is either performed at the chromosomal level by fluorescence in situ hybridiza tion or at the RNA level by reversetranscriptase quan titative PCR. Using these techniques, PAX8-PPARG rearrangements have been found in about onethird of FTC and substantially less frequently in other thy roid tumours; however, data from other thyroid tumours vary between publications. [26] [27] [28] [29] [30] 61, [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] Although the sample size was small, a comparison of FTC with (n = 6) and with out (n = 43) PPFP showed no significant differences in the extent of capsular or vascular invasion, diseasefree surviv al or overall survival. 76 PPFP as an oncoprotein vector only. 77 Expression of PPFP also decreased the rate of apoptosis in these cells, which might be partially responsible for the detection of accelerated growth. 77 In addition, PPFP expression in FRTL5 rat thyroid cells resulted in increased DNA synthesis, which was shown by increased 3 Hthymidine incorporation. 78 Nthyori 31 cells 77 and rat thyroid PCCL3 cells 79 that stably express PPFP exhibit increased anchorageindependent growth, demonstrated by their ability to form colonies in soft agar, a hallmark of cellular transformation. Expression of either PPFP or a CREB3like protein 2-PPARγ fusion protein in primary human thyroid cells resulted in an increased number of cells and increased DNA synthe sis, 31 suggesting that the PPARγ moiety of these fusion proteins is at least partially responsible for their onco genic actions. Although little else is known regarding the function of CREB3like protein 2-PPARγ, further com parison of this fusion protein with PPFP has the poten tial to reveal important insights into the mechanisms of oncogenesis.
In the U2OS human osteosarcoma cell line, transfec tion with PPARγ resulted in transactivation of PPARγ response elements, whereas transfection with PPFP did not. 61 Furthermore, coexpression of PPFP with PPARγ abrogated PPARγmediated reporter gene expression in a dominantnegative fashion. These observations are important because some evidence suggests that PPARγ could have antitumour or tumoursuppressor properties, which implies that the oncogenic effects of PPFP might result from inhibition of the activity of endogenous PPARγ. In PPARγexpressing ATC cell lines, treatment with a PPARγ agonist increased the proportion of quies cent cells (in G0 and G1 phases) and increased expression of the cellcycle progression inhibitors p21 cip1 and p27 kip1 , suggesting decreased proliferation. 80 DNA synthesis was also reduced. 80 Similarly, human thyroid cancer cell lines engi neered to overexpress PPARγ showed decreased colony formation in soft agar, nuclear condensation, chro matin fragmentation, apoptosis and cell cycle arrest. 64, [80] [81] [82] PPARγ might, therefore, have an antitumour effect in some thyroid cell lines, and similar findings have also been obtained in several nonthyroidal cell lines. [83] [84] [85] [86] [87] [88] In vivo evidence also supports the idea that PPARγ might have antitumour properties. For example, mice with a homozygous knockin mutation in Thrb (which encodes thyroid hormone receptor β) unexpectedly devel oped thyroid carcinoma, and the disease became more aggressive in the presence of a singleallele deletion of Pparg. 89 Although the above data suggest a simple story that endogenous PPARγ is a thyroid cancer tumour suppres sor and that PPFP is oncogenic by virtue of dominant negative activity against nonmutant PPARγ, the actual situation is likely to be more complex. Firstly, PPARγ is expressed at extremely low levels in the normal thyroid 90 and whether it has any function in that organ is not known. Secondly, microarray data from human thy roid carcinomas strongly suggest that PPFP has PPARγlike activity in these tumours. 73, 91 For example, compared with PPFPnegative thyroid carcinomas, two of the most strongly upregulated genes in PPFPpositive carcinomas are AQP7 and ANGPTL4, 73, 91 and expression of both these genes is well known to be induced by PPARγ in adipocytes. Furthermore, transfection experiments show that PPFP activates the AQP7 promoter in a PPARγ like manner in both thyroid and nonthyroid cell types. 73 In addition, high levels of expression of endogenous PPARγ seem to contribute to the aggressive behaviour of human ATC, at least in cell culture and after ortho topic injections in mice. 92 Finally, PPARγ antagonists have antiproliferative effects in a wide variety of cancer cell lines. 93 The expression of PPFP in transgenic mice is apparently not sufficient to cause thyroid cancer, which is consistent with the observation that benign thyroid adenomas do occasionally express PPFP. However, transgenic mice with thyroidspecific expression of PPFP and thyroidspecific homozygous deletion of Pten develop metastatic thyroid carcinoma (hereafter denoted PPFP Thy ;Pten Thy-/-mice). 94 Deletion of Pten was added to the PPFP mouse model because it results in increased amounts of (activated) phosphorylated Akt, as is observed in human PPFP positive carcinomas. 95 Increased phosphorylation of Akt, which is common in FTC in general and is not specific of PPFPpositive carcinomas, 42 can result from a variety of genetic or epigenetic events.
Importantly, treatment with the PPARγ agonist pio gli tazone dramatically decreased the size of thyroid car cinomas and completely prevented metastatic disease in PPFP Thy ;Pten Thy-/-thyroid carcinoma mice. 94 Most remarkably, pioglitazone caused an adipogenic response in the remaining thyroid cancer cells, manifested in lipid accumulation and induction of a broad array of PPARγ target genes that are expressed in adipocytes, in keeping with the role of PPARγ as the master regulator of adipo genesis. 50 These findings indicate that, in the presence of pioglitazone, PPFP has very strong PPARγlike effects. The reader should note that Pten Thy-/-mice that do not express PPFP develop benign thyroid hyperplasia that is unaffected by pioglitazone. 94 Interestingly, evidence also suggests that PPFP might inhibit tumorigenesis in vivo by inhibiting angio genesis. 96 Although ectopic expression of PPFP in immortalized thyrocytes led to increased growth and decreased apop tosis in vitro, xenografts of these cells in mice showed decreased tumour growth in vivo. 96 Further investi gation of the xenograft tumours identified reduced expression of CD31 (an endothelial cell marker) 97 and VEGF (an angiogenesisstimulating factor important in neo vascularization), 98 suggesting that PPFP expres sion inhibits neovascularization. 96 Expression of tissue inhibitor of metalloproteinases 3 (TIMP3), an inhibitor of angio genesis, was also increased in these tumour cells, which was considered a potential explanation for these findings. 96 However, expression of TIMP3 is repressed, not induced, in PPFPpositive FTC obtained from patients.
73,91

Cellular transformation and PPFP
Although the specific mechanism of action of PPFP is yet to be defined, PPFP can act as a dominantnegative inhibitor of wildtype PPARγ and/or as a unique tran scriptional activator of a subset of PPARγresponsive genes. In thyroid carcinomas, PPFP is expressed at levels 10-50fold higher than those of endogenous PPARγ. 73, 91 PPFP also has mixed actions on Pax8 target genes in transfection experiments. Of note, PPFP includes the DNAbinding domains and transcriptionregulatory domains of both Pax8 and PPARγ. Consequently, PPFP has the potential to bring inappropriate transcrip tional coregulators to Pax8 and PPARγ target genes. There fore, one plausible mechanism of PPFPmediated oncogenesis is the modulation of signalling pathways downstream of Pax8 or PPARγ.
Pax8 is required for normal thyroid development and is important in the maintenance of differentiated follicu lar cell function. When PPFP is expressed in human thyroid cancer cell lines, the Pax8responsive genes SLC5A5, TPO, TG and TSHR (which encodes thyrotropin receptor, also known as thyroidstimulating hormone [TSH] receptor) were variably stimulated or inhibited. For example, PPFP expression stimulated transcription of SLC5A5 and TPO, whereas it repressed transcription of TG in a celltypespecific manner. 78 In Nthyori 31 cells, PPFP did not affect basal expression of endogenous thyroglobulin and TSH receptor but inhib ited the ability of Pax8 to induce thyroglobulin and TSH receptor expression. 99 In other studies, PPFP repressed basal expression of a reporter gene that was driven by the TG promoter. 78 The molecular basis for the variable effects of PPFP on Pax8responsive genes is not known. Other Pax tran scription factors are associated with various cancers. 100 For example, gene fusions of PAX3 or PAX7 with FOXO1 (previously denoted FKHR) underlie alveolar rhabdomyosarcomas, gene fusions of PAX5 with IGH are found in lymphomas, and overexpression of Pax2 occurs in a variety of cancers. The Pax8 portion of PPFP (which is structurally related to the other Pax transcrip tion fac tors) might, therefore, be actively involved in its oncogenic action.
PPARγ is a nuclear hormone receptor that is expressed at very low levels in the normal thyroid and has, to date, no identified function in that organ. In vitro studies indicate that PPFP can inhibit the function of wildtype PPARγ. Hence, the concept that oncogenic effects of PPFP might involve the inhibition of postulated tumour suppres sor activities of endogenous PPARγ remains attractive. However, PPFP can clearly also act in a PPARγlike manner. 73, 91 In vitro, PPFP stimulates the promoters of some PPARγ target genes and represses others. 73, 77, 78 A comparison of gene expression profiling data from FTC that express PPFP versus those that do not express the fusion protein demonstrated that PPFPposi tive cancers have a distinct transcriptional signature. 73, 91, 101 Two studies 73, 91 yielded highly concordant data: numerous PPARγ target genes that are upregulated in adipocytes (such as AQP7 and ANGPTL4) were also upregulated in PPFPpositive carcinomas, and transcripts of genes linked to pathways such as fatty acid metabolism and βoxidation were highly enriched. Notably, a number of genes already associated with cancer were identified in these data sets. For example, in both studies, expression of MYCL and NRG1 was induced in PPFPpositive tumours. In addition, expression of FGFBP1, PGF and ANGPTL4 (which encode proangiogenic factors) was induced and expression of TIMP3 (which encodes an antiangiogenic factor) was repressed. However, for unclear reasons, the gene expression profile identified in PPFPpositive thyroid carcinomas by another group of investigators had virtually no overlap with the above studies; 101 instead, PPFPpositive tumours showed upregulated expression of genes associated with signal transduction, cell growth and translational control, and repressed expression of genes encoding ribosomal proteins and translationassociated genes. 101 However, an important limitation in the inter pretation of gene expression profiling data from PPFP positive thyroid carcinomas is that the specific genes essential for oncogenesis are not known.
Stable expression of PPFP in the rat thyroid cell line PCCL3 activated the Wnt-Tcellspecific transcrip tion factor (TCF) pathway in a subset of cells. 79 This TCFactive fraction had an improved ability to grow under anchorageindependent conditions, and to invade through a synthetic basement membrane. In addition, thyroids from PPFP Thy ;Pten Thy-/-carcinoma mice showed induction of expression of a number of Wnt-TCF tar get genes. These observations are potentially important because activation of the Wnt-TCF pathway is a central component of the cell biology in normal stem cells, as well as in cancer stem cells from a variety of organs, such as the colon. 102 In fact, the PPFPexpressing PCCL3 cells were hierarchically organized so that TCFactive cells gave rise to both TCFactive and TCFinactive cells, whereas TCF inactive cells only gave rise to TCFinactive cells. This hierarchical organization is typical of stem cells. Thus, it is possible that PPFP activates thyroid cancer stem cells via the induction of TCFresponsive genes.
Clinical implications
PPFP as a diagnostic tool PPFP is primarily found in FTC and follicularvariant PTC. However, FTC cannot be identified by cytological analysis of FNA biopsy specimens because the diagnosis of FTC requires evidence of invasion. This is a major reason why ~20-25% of thyroid FNA biopsy samples are considered cytologically indeterminate. Evidence is accu mulating that the use of molecular analyses in this situa tion results in improved discrimination of benign versus malignant thyroid nodules. For example, in one study, 16 thyroid nodules contained PAX8-PPARG mRNA in their biopsy specimens. Upon surgical removal of 14 of the 16 thyroid nodules, all 14 were found to be malignant even though none could be diagnosed as cancer on the basis of the cytology of their biopsy specimens. 103 The impli cation of these findings is that expression of PPFP in a thyroid nodule biopsy sample with indeterminate cytol ogy indicates the need for surgery. Thus, identification of PPFP (along with other driver mutations) is a promising approach to improve clinical decisionmaking in patients with indeterminate findings at thyroid nodule biopsy.
PPFP as a therapeutic target
Synthetic ligands such as thiazolidinediones are potent acti vators of PPARγ with robust insulinsensitizing activ ity and are used in the treatment of type 2 dia betes mellitus. 104 As described above, treatment with the PPARγ agonist pioglitazone is highly therapeutic in PPFP Thy ;Pten Thy-/-mice models of thyroid carcinoma, in which treatment with this drug greatly reduced the size of the primary tumour and eliminated metastatic dis ease. 94 These data suggest that treatment with pio glitazone could be beneficial in patients with PPFP positive thyroid carcinoma, a hypothesis being tested in an ongoing phase II clinical trial in patients with advanced disease not amenable to cure by surgery or radioiodine. 105 Positive results in this trial would be espe cially notable because pio glitazone is already approved by the FDA for the longterm therapy of type 2 dia betes mellitus, and has very little toxicity compared with other targeted chemo therapeutic agents such as tyrosine kinase inhibitors. Pioglitazone is a ligand for PPFP that turns this fusion protein into a transcription factor with strong PPARγlike effects, which in mice results in trans differentiation of PPFPexpressing thyroid cancer cells into adipocytelike cells. We presume that the cancer cells lose their malignant character as they gain the charac teristics of differentiated adipocytes. This notion is supported by limited observations that a nonadipogenic PPARγ agonist with full insulinsensitizing proper ties had no antitumour effect in PPFP Thy ;Pten Thy-/-mice models of thyroid carcinoma. 79 Thus, although the pro adipogenic action of pioglitazone is considered an unwanted adverse effect in patients receiving this agent as therapy for diabetes mellitus, this action prob ably is integral to the thera peutic effect of pioglitazone in PPFPpositive thyroid carcinoma.
Conclusions
The t(2;3)(q13;p25) chromosomal translocation that results in PAX8-PPARG gene fusion and expression of PPFP is a driver mutation found in ~30-35% of FTC as well as a subset of follicularvariant PTC. PPFP can act as a dominantnegative inhibitor of PPARγ or as a PPARγ like transcription factor depending on the target gene and cellular context. PPFP also has variable effects on Pax8 target genes. We presume that modulation of subsets of these pathways underlies the variable oncogenic actions of PPFP.
Cytological criteria are insufficient to differentiate FTC from benign lesions in thyroid biopsy specimens; thus, the identification of PPFP as an oncoprotein has important clinical implications. The detection of PPFP in thyroid biopsy samples with indeterminate cytology pro vides evidence that the nodule is highly likely to be malig nant and that surgery is indicated. Although the majority of patients with thyroid cancer are cured by surgery with or without radioiodine therapy, cure can be difficult or impossible in patients with locally recurrent or distant metastatic disease. Novel therapeutic approaches are, therefore, necessary for the management of these patients.
Since pioglitazone treatment has highly therapeu tic effects in PPFP Thy ;Pten Thy-/-mice, this drug is cur rently being investigated in patients with advanced PPFPpositive thyroid carcinoma. 105 However, the pro adipogenic actions of pioglitazone as a PPFP ligand prob ably underlie its therapeutic efficacy, a point that needs to be kept in mind if additional PPARγ agonists are tested in this disease.
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